Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis

Altered metabolism of glucose, lipid and glutamine is a prominent hallmark of cancer cells. Currently, cell heterogeneity is believed to be the main cause of poor prognosis of glioblastoma (GBM) and is closely related to relapse caused by therapy resistance. However, the comprehensive model of genes...

Full description

Bibliographic Details
Main Authors: Zheng He, Chengcheng Wang, Hao Xue, Rongrong Zhao, Gang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01631/full
_version_ 1828554045473685504
author Zheng He
Zheng He
Zheng He
Chengcheng Wang
Hao Xue
Hao Xue
Hao Xue
Rongrong Zhao
Rongrong Zhao
Rongrong Zhao
Gang Li
Gang Li
Gang Li
author_facet Zheng He
Zheng He
Zheng He
Chengcheng Wang
Hao Xue
Hao Xue
Hao Xue
Rongrong Zhao
Rongrong Zhao
Rongrong Zhao
Gang Li
Gang Li
Gang Li
author_sort Zheng He
collection DOAJ
description Altered metabolism of glucose, lipid and glutamine is a prominent hallmark of cancer cells. Currently, cell heterogeneity is believed to be the main cause of poor prognosis of glioblastoma (GBM) and is closely related to relapse caused by therapy resistance. However, the comprehensive model of genes related to glucose-, lipid- and glutamine-metabolism associated with the prognosis of GBM remains unclear, and the metabolic heterogeneity of GBM still needs to be further explored. Based on the expression profiles of 1,395 metabolism-related genes in three datasets of TCGA/CGGA/GSE, consistent cluster analysis revealed that GBM had three different metabolic status and prognostic clusters. Combining univariate Cox regression analysis and LASSO-penalized Cox regression machine learning methods, we identified a 17-metabolism-related genes risk signature associated with GBM prognosis. Kaplan-Meier analysis found that obtained signature could differentiate the prognosis of high- and low-risk patients in three datasets. Moreover, the multivariate Cox regression analysis and receiver operating characteristic curves indicated that the signature was an independent prognostic factor for GBM and had a strong predictive power. The above results were further validated in the CGGA and GSE13041 datasets, and consistent results were obtained. Gene set enrichment analysis (GSEA) suggested glycolysis gluconeogenesis and oxidative phosphorylation were significantly enriched in high- and low-risk GBM. Lastly Connectivity Map screened 54 potential compounds specific to different subgroups of GBM patients. Our study identified a novel metabolism-related gene signature, in addition the existence of three different metabolic status and two opposite biological processes in GBM were recognized, which revealed the metabolic heterogeneity of GBM. Robust metabolic subtypes and powerful risk prognostic models contributed a new perspective to the metabolic exploration of GBM.
first_indexed 2024-12-12T05:29:13Z
format Article
id doaj.art-d9696f5b8b2440a6846d25e4b0707332
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-12T05:29:13Z
publishDate 2020-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-d9696f5b8b2440a6846d25e4b07073322022-12-22T00:36:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-09-011010.3389/fonc.2020.01631565793Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic AnalysisZheng He0Zheng He1Zheng He2Chengcheng Wang3Hao Xue4Hao Xue5Hao Xue6Rongrong Zhao7Rongrong Zhao8Rongrong Zhao9Gang Li10Gang Li11Gang Li12Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaShandong Key Laboratory of Brain Function Remodeling, Jinan, ChinaInstitute of Brain and Brain-Inspired Science, Shandong University, Jinan, ChinaDepartment of Pharmacy, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, ChinaDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaShandong Key Laboratory of Brain Function Remodeling, Jinan, ChinaInstitute of Brain and Brain-Inspired Science, Shandong University, Jinan, ChinaDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaShandong Key Laboratory of Brain Function Remodeling, Jinan, ChinaInstitute of Brain and Brain-Inspired Science, Shandong University, Jinan, ChinaDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaShandong Key Laboratory of Brain Function Remodeling, Jinan, ChinaInstitute of Brain and Brain-Inspired Science, Shandong University, Jinan, ChinaAltered metabolism of glucose, lipid and glutamine is a prominent hallmark of cancer cells. Currently, cell heterogeneity is believed to be the main cause of poor prognosis of glioblastoma (GBM) and is closely related to relapse caused by therapy resistance. However, the comprehensive model of genes related to glucose-, lipid- and glutamine-metabolism associated with the prognosis of GBM remains unclear, and the metabolic heterogeneity of GBM still needs to be further explored. Based on the expression profiles of 1,395 metabolism-related genes in three datasets of TCGA/CGGA/GSE, consistent cluster analysis revealed that GBM had three different metabolic status and prognostic clusters. Combining univariate Cox regression analysis and LASSO-penalized Cox regression machine learning methods, we identified a 17-metabolism-related genes risk signature associated with GBM prognosis. Kaplan-Meier analysis found that obtained signature could differentiate the prognosis of high- and low-risk patients in three datasets. Moreover, the multivariate Cox regression analysis and receiver operating characteristic curves indicated that the signature was an independent prognostic factor for GBM and had a strong predictive power. The above results were further validated in the CGGA and GSE13041 datasets, and consistent results were obtained. Gene set enrichment analysis (GSEA) suggested glycolysis gluconeogenesis and oxidative phosphorylation were significantly enriched in high- and low-risk GBM. Lastly Connectivity Map screened 54 potential compounds specific to different subgroups of GBM patients. Our study identified a novel metabolism-related gene signature, in addition the existence of three different metabolic status and two opposite biological processes in GBM were recognized, which revealed the metabolic heterogeneity of GBM. Robust metabolic subtypes and powerful risk prognostic models contributed a new perspective to the metabolic exploration of GBM.https://www.frontiersin.org/article/10.3389/fonc.2020.01631/fullglioblastomametabolismprognosissignatureheterogeneity
spellingShingle Zheng He
Zheng He
Zheng He
Chengcheng Wang
Hao Xue
Hao Xue
Hao Xue
Rongrong Zhao
Rongrong Zhao
Rongrong Zhao
Gang Li
Gang Li
Gang Li
Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
Frontiers in Oncology
glioblastoma
metabolism
prognosis
signature
heterogeneity
title Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
title_full Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
title_fullStr Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
title_full_unstemmed Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
title_short Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
title_sort identification of a metabolism related risk signature associated with clinical prognosis in glioblastoma using integrated bioinformatic analysis
topic glioblastoma
metabolism
prognosis
signature
heterogeneity
url https://www.frontiersin.org/article/10.3389/fonc.2020.01631/full
work_keys_str_mv AT zhenghe identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT zhenghe identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT zhenghe identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT chengchengwang identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT haoxue identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT haoxue identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT haoxue identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT rongrongzhao identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT rongrongzhao identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT rongrongzhao identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT gangli identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT gangli identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis
AT gangli identificationofametabolismrelatedrisksignatureassociatedwithclinicalprognosisinglioblastomausingintegratedbioinformaticanalysis